Omega Therapeutics Inc (OMGA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Omega Therapeutics Inc (OMGA) has a cash flow conversion efficiency ratio of -1.214x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.02 Million) by net assets ($11.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Omega Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2023)
This chart illustrates how Omega Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read OMGA total debt and obligations for a breakdown of total debt and financial obligations.
Omega Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Omega Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Henry Boot PLC
LSE:BOOT
|
-0.039x |
|
Brooks Macdonald Group
LSE:BRK
|
0.107x |
|
Multipolar Tbk
JK:MLPL
|
0.015x |
|
Oragenics Inc
NYSE MKT:OGEN
|
-0.342x |
|
X2M Connect Ltd
AU:X2M
|
-0.024x |
|
Wescan Goldfields Inc
V:WGF
|
0.219x |
|
Sherborne Investors Guernsey C Ltd
LSE:SIGC
|
-0.005x |
|
Olivers Real Food Ltd
AU:OLI
|
0.004x |
Annual Cash Flow Conversion Efficiency for Omega Therapeutics Inc (2019–2023)
The table below shows the annual cash flow conversion efficiency of Omega Therapeutics Inc from 2019 to 2023. For the full company profile with market capitalisation and key ratios, see how much is Omega Therapeutics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $58.02 Million | $-91.51 Million | -1.577x | -69.67% |
| 2022-12-31 | $105.97 Million | $-98.52 Million | -0.930x | -223.76% |
| 2021-12-31 | $200.63 Million | $-57.61 Million | -0.287x | -171.01% |
| 2020-12-31 | $-64.63 Million | $-26.13 Million | 0.404x | -7.37% |
| 2019-12-31 | $-35.92 Million | $-15.68 Million | 0.437x | -- |
About Omega Therapeutics Inc
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epig… Read more